Home LiteratureArticle Details
PMID: 6415113 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

The Journal of clinical investigation ·Vol. 72 ·No. 5 ·1983-11-00 ·Pages 1532-42

Miller JL, Kupinski JM, Castella A, Ruggeri ZM

Abstract

Platelet-type von Willebrand disease (vWD) and pseudo-vWD are two recently described intrinsic platelet defects characterized by enhanced ristocetin-induced agglutination in platelet-rich plasma. A similar finding is also typical of type IIB vWD, where it has been related to a von Willebrand factor (vWF) rather than a platelet abnormality. Platelet aggregation induced by unmodified human vWF in the absence of other stimuli has been reported in pseudo-vWD. In this study we demonstrate that vWF induces aggregation in platelet-type but not type IIB vWD. Aggregation is observed when normal plasma cryoprecipitate or purified vWF are added to platelet-rich plasma. Cryoprecipitate also aggregates washed platelets, although at higher concentrations than required for platelet-rich plasma. Purified vWF, however, induces significant aggregation of washed platelets only when plasma is added. EDTA inhibits vWF-induced aggregation. Its effect can be overcome by calcium but much less effectively by magnesium ions. Unstimulated platelets in platelet-rich plasma from patients with platelet-type but not type IIB vWD bind 125I-vWF in a specific and saturable manner. All different sized multimers of vWF become associated with platelets. Both aggregation and binding exhibit a similar vWF concentration dependence, suggesting that a correlation exists between these two events. Removal of ADP by appropriate consuming systems is without effect upon such binding or upon vWF-induced aggregation. Thrombin-induced 125I-vWF binding to washed platelets is normal in platelet-type as well as type IIB vWD. These results demonstrate that a specific binding site for unmodified human vWF is exposed on unstimulated platelets in platelet-type vWD. The relatively high vWF concentrations required for aggregation and binding may explain the lack of significant in vivo aggregation and thrombocytopenia in these patients. Moreover, these studies provide additional evidence that platelet-type and type IIB vWD are different diseases with distinct pathogeneses.

MeSH Terms
Adenosine Diphosphate/pharmacology Apyrase/pharmacology Blood Coagulation Factors/physiology Blood Platelets/metabolism Factor VIII/pharmacology Female Fibrinogen/pharmacology Humans Male Platelet Aggregation/drug effects Thrombin/pharmacology von Willebrand Diseases/blood von Willebrand Factor/physiology
Chemicals
Blood Coagulation Factors cryoprecipitate coagulum von Willebrand Factor Adenosine Diphosphate Factor VIII Fibrinogen Thrombin Apyrase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Miller J L
Kupinski J M
Castella A
Ruggeri Z M
References (29)
29 references, click to expand
  1. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  2. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.
    Br J Haematol. 1971 Jul;21(1):1-20 PMID: 5559480
  3. Ristocetin--a new tool in the investigation of platelet aggregation.
    Thromb Diath Haemorrh. 1971 Oct 31;26(2):362-9 PMID: 5316292
  4. Aggregation of human platelets by purified porcine and bovine antihaemophilic factor.
    Nat New Biol. 1973 Jan 31;241(109):149-50 PMID: 4512618
  5. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis.
    Am J Med. 1974 Dec;57(6):920-5 PMID: 4473891
  6. Membrane receptors and hormone action.
    Adv Protein Chem. 1976;30:251-451 PMID: 180780
  7. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.
    J Clin Invest. 1976 Apr;57(4):925-37 PMID: 1084890
  8. Metabolism and function of human platelets washed by albumin density gradient separation.
    Br J Haematol. 1977 Jun;36(2):287-96 PMID: 871437
  9. Factor VIII-related properties in platelets from patients with von Willebrand's disease.
    J Lab Clin Med. 1978 Jan;91(1):132-40 PMID: 304081
  10. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.
    Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57 PMID: 637870
  11. von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.
    J Clin Invest. 1978 Jun;61(6):1498-507 PMID: 307007
  12. Heterogeneity of human factor VIII. II. Characterization of forms of factor VIII binding to platelets in the presence of ristocetin.
    J Lab Clin Med. 1978 Jul;92(1):96-107 PMID: 659967
  13. Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.
    J Clin Invest. 1979 Apr;63(4):656-64 PMID: 108291
  14. Human platelet membrane receptor for bovine von Willebrand factor (platelet aggregating factor): an integral membrane glycoprotein.
    Proc Natl Acad Sci U S A. 1979 Mar;76(3):1069-73 PMID: 312498
  15. Human platelets possess an inducible and saturable receptor specific for fibrinogen.
    J Biol Chem. 1979 Jun 25;254(12):5357-63 PMID: 447655
  16. Statistical analysis of enzyme kinetic data.
    Methods Enzymol. 1979;63:103-38 PMID: 502857
  17. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
    Proc Natl Acad Sci U S A. 1979 Oct;76(10):5317-20 PMID: 315561
  18. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
    N Engl J Med. 1980 May 8;302(19):1047-51 PMID: 6767976
  19. The complex multimeric composition of factor VIII/von Willebrand factor.
    Blood. 1981 Jun;57(6):1140-3 PMID: 6784794
  20. Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets.
    Blood. 1981 Aug;58(2):387-97 PMID: 6788111
  21. Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.
    J Clin Invest. 1981 Aug;68(2):321-8 PMID: 6790574
  22. Mechanism of binding of multivalent immune complexes to Fc receptors. 1. Equilibrium binding.
    Biochemistry. 1981 Oct 27;20(22):6326-34 PMID: 7306512
  23. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
    N Engl J Med. 1982 Feb 11;306(6):326-33 PMID: 6798442
  24. Adenosine diphosphate induces binding of von Willebrand factor to human platelets.
    Nature. 1982 May 13;297(5862):154-6 PMID: 6281653
  25. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets.
    J Clin Invest. 1982 Jun;69(6):1212-22 PMID: 6282932
  26. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder.
    Blood. 1982 Sep;60(3):790-4 PMID: 6286015
  27. Platelets have more than one binding site for von Willebrand factor.
    J Clin Invest. 1983 Jul;72(1):1-12 PMID: 6223940
  28. Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets.
    Proc Natl Acad Sci U S A. 1982 Oct;79(19):6038-41 PMID: 6310559
  29. A new method for the determination of fibrinogen in small samples of plasma.
    J Lab Clin Med. 1951 Feb;37(2):316-20 PMID: 14814359
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1983-11-00
Pages
1532-42
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC370441
Subset
IM
Grants
NCRR NIH HHS · 2707RR05402-20 · United States
NHLBI NIH HHS · HL-30265 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com